HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 3 (2006), Issue 6 (June)

1. New, extended hairpin form of the TAR-2 RNA domain points to the structural polymorphism at the 5' end of the HIV-2 leader RNA.
   Nucleic Acids Res, 34(10): 2984-97. [Abstract] [Full-text]
2. Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
   Bioorg Med Chem Lett, 16(13): 3430-3. [Abstract] [Full-text]
3. Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
   Bioorg Med Chem Lett, 16(13): 3541-4. [Abstract] [Full-text]
4. Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients.
   J Infect Dis, 194(1): 38-41. [Abstract] [Full-text]
5. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
   J Infect Dis, 194(1): 29-37. [Abstract] [Full-text]
6. A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads.
   J Infect Dis, 194(1): 20-8. [Abstract] [Full-text]
7. The survival benefits of AIDS treatment in the United States.
   J Infect Dis, 194(1): 11-9. [Abstract] [Full-text]
8. HIV-1 Tat depresses DNA-PK(CS) expression and DNA repair, and sensitizes cells to ionizing radiation.
   Int J Radiat Oncol Biol Phys, 65(3): 842-50. [Abstract] [Full-text]
9. Effects of transdermal testosterone administration on insulin sensitivity, fat mass and distribution, and markers of inflammation and thrombolysis in human immunodeficiency virus-infected women with mild to moderate weight loss.
   Fertil Steril, 85(6): 1794-802. [Abstract] [Full-text]
10. Knowledge, attitude and practice towards HIV/AIDS in a rural Kenyan community.
    J Biosoc Sci, 38(4): 481-90. [Abstract] [Full-text]
11. Health of Indigenous people in Africa.
    Lancet, 367(9526): 1937-46. [Abstract] [Full-text]
12. Altered hippocampal-prefrontal activation in HIV patients during episodic memory encoding.
    Neurology, 66(11): 1688-95. [Abstract] [Full-text]
13. HIV neuropathy natural history cohort study: assessment measures and risk factors.
    Neurology, 66(11): 1679-87. [Abstract] [Full-text]
14. Discontinuation of maintenance therapy against toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapy.
    Clin Microbiol Infect, 12(7): 666-71. [Abstract] [Full-text]
15. Analysis of the influence of therapy and viral suppression on high-risk sexual behaviour and sexually transmitted infections among patients infected with human immunodeficiency virus in Taiwan.
    Clin Microbiol Infect, 12(7): 660-5. [Abstract] [Full-text]
16. Distribution and three-dimensional structure of AIDS virus envelope spikes.
    Nature, 441(7095): 847-52. [Abstract] [Full-text]
17. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.
    Clin Infect Dis, 43(2): 253-5. [Abstract] [Full-text]
18. Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children.
    Clin Infect Dis, 43(2): 243-52. [Abstract] [Full-text]
19. Case management is associated with improved antiretroviral adherence and CD4+ cell counts in homeless and marginally housed individuals with HIV infection.
    Clin Infect Dis, 43(2): 234-42. [Abstract] [Full-text]
20. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review.
    Clin Infect Dis, 43(2): 223-33. [Abstract] [Full-text]
21. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells.
    J Infect Dis, 194(2): 247-55. [Abstract] [Full-text]
22. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.
    J Infect Dis, 194(2): 238-46. [Abstract] [Full-text]
23. Predictors of participation in an HIV risk reduction intervention for socially deprived Latino women: a cross sectional cohort study.
    Int J Nurs Stud, 43(5): 527-34. [Abstract] [Full-text]
24. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial.
    Lancet, 367(9527): 1981-9. [Abstract] [Full-text]
25. An educational HIV pretest counseling video program for off-hours testing in the emergency department.
    Ann Emerg Med, 48(1): 21-7. [Abstract] [Full-text]
26. Changing spectrum of the diffuse infiltrative lymphocytosis syndrome.
    Arthritis Rheum, 55(3): 466-72. [Abstract] [Full-text]
27. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy.
    Metabolism, 55(7): 940-5. [Abstract] [Full-text]
28. Endocrine effects of oral dehydroepiandrosterone in men with HIV infection: a prospective, randomized, double-blind, placebo-controlled trial.
    Metabolism, 55(7): 858-70. [Abstract] [Full-text]
29. Effects of signal peptide exchange on HIV-1 glycoprotein expression and viral infectivity in mammalian cells.
    FEBS Lett, 580(15): 3775-8. [Abstract] [Full-text]
30. Performance evaluation of the two protease sequencing primers of the Trugene HIV-1 genotyping kit.
    J Virol Methods, 135(2): 137-42. [Abstract] [Full-text]
31. Comparison of the COBAS TAQMAN HIV-1 HPS with VERSANT HIV-1 RNA 3.0 assay (bDNA) for plasma RNA quantitation in different HIV-1 subtypes.
    J Virol Methods, 135(2): 223-8. [Abstract] [Full-text]
32. Novel, rapid assay for measuring entry of diverse enveloped viruses, including HIV and rabies.
    J Virol Methods, 135(2): 143-50. [Abstract] [Full-text]
33. Environmental risk factors for infection with Mycobacterium avium complex.
    Am J Epidemiol, 164(1): 32-40. [Abstract] [Full-text]
34. HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case-control study.
    BMC Cancer, 6: 135. [Abstract] [Full-text]
35. Adaptation to different human populations by HIV-1 revealed by codon-based analyses.
    PLoS Comput Biol, 2(6): e62. [Abstract] [Full-text]
36. On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials.
    PLoS Comput Biol, 2(6): e64. [Abstract] [Full-text]
37. STI/HIV risks for Mexican migrant laborers: exploratory ethnographies.
    J Immigr Minor Health, 8(3): 291-302. [Abstract] [Full-text]
38. HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients.
    Transplantation, 81(12): 1658-61. [Abstract] [Full-text]
39. Reform of drug control policy for palliative care in Romania.
    Lancet, 367(9528): 2110-7. [Abstract] [Full-text]
40. Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5' long terminal repeat domain.
    Clin Chem, 52(7): 1258-66. [Abstract] [Full-text]
41. Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile.
    Antiviral Res, 71(1): 15-23. [Abstract] [Full-text]
42. Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment.
    Antiviral Res, 71(1): 42-52. [Abstract] [Full-text]
43. The membranes' role in the HIV-1 neutralizing monoclonal antibody 2F5 mode of action needs re-evaluation.
    Antiviral Res, 71(1): 69-72. [Abstract] [Full-text]
44. Complete genomic sequences for hepatitis C virus subtypes 6e and 6g isolated from Chinese patients with injection drug use and HIV-1 co-infection.
    J Med Virol, 78(8): 1061-9. [Abstract] [Full-text]
45. Molecular epidemiology of HIV-1 subtypes based on analysis of pol sequences in Slovenia, 1996-2005.
    J Med Virol, 78(8): 997-1002. [Abstract] [Full-text]
46. Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART.
    J Med Virol, 78(8): 1003-10. [Abstract] [Full-text]
47. A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany.
    Epidemiol Infect, 134(4): 814-9. [Abstract] [Full-text]
48. Multisectoral responses to HIV/AIDS: applying research to policy and practice.
    Am J Public Health, 96(7): 1189-91. [Abstract] [Full-text]
49. Immune reconstitution syndrome precipitated by bacille Calmette Guerin after initiation of antiretroviral therapy.
    Pediatr Infect Dis J, 25(7): 648-9. [Abstract] [Full-text]
50. Immune reconstitution syndrome from nontuberculous mycobacterial infection after initiation of antiretroviral therapy in children with HIV infection.
    Pediatr Infect Dis J, 25(7): 645-8. [Abstract] [Full-text]
51. Hospitalization trends among children and youths with perinatal human immunodeficiency virus infection, 1990-2002.
    Pediatr Infect Dis J, 25(7): 628-33. [Abstract] [Full-text]
52. Observational cohort study of HIV-infected African children.
    Pediatr Infect Dis J, 25(7): 623-7. [Abstract] [Full-text]
53. Genetic attributes of cerebrospinal fluid-derived HIV-1 env.
    Brain, 129: 1872-83. [Abstract] [Full-text]
54. HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients.
    Clin Infect Dis, 43(3): 377-80. [Abstract] [Full-text]
55. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients.
    Clin Infect Dis, 43(3): 365-72. [Abstract] [Full-text]
56. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
    Clin Infect Dis, 43(3): 357-64. [Abstract] [Full-text]
57. Management of herpes simplex virus type 2 infection in HIV type 1-infected persons.
    Clin Infect Dis, 43(3): 347-56. [Abstract] [Full-text]
58. Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women.
    Am J Epidemiol, 164(2): 176-83. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.